Drug Approval | January 12, 2026
FDA rejects Vanda’s jet lag drug in current form
Vanda strongly disputes the FDA’s reasoning
Vanda strongly disputes the FDA’s reasoning
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The approval is backed by data showing deep, durable responses and manageable tolerability
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
Subscribe To Our Newsletter & Stay Updated
